The acquisition, pathologic characterization and molecular analysis of human and mouse Gl tissue samples is a fundamental and integral for all projects of this SPORE application. The Dana-Farber / Harvard Cancer Center (DF/HCC) SPORE in Gastrointestinal (Gl) Cancer Tissue and Pathology Core will continue to provide basic and advance pathology services to SPORE investigators in support the studies outlined in each of the Research Projects, as well as in Career Development and Developmental Projects. The Tissue and Pathology Core will collect, store and provide tissue specimens, through interactions with Gl Tumor banks and the DF/HCC Pathology Specimen Locator, perform histologic analyses and provide interpretive pathologic analysis of human esophageal, colonic, pancreatic and Gl stromal tumors (GISTs). The Core will ensure that appropriately classified Gl cancer tissue samples are used and supplied for all immunohistochemical and molecular analyses proposed. In addition, the Core is committed to the characterization of gastrointestinal neoplasms using advanced molecular pathology tools. A variety of services critical to successful molecular analysis of mouse and human Gl tumors will be provided, including;histopathologic review and quality control analysis of all tumor samples utilized in experimental studies;construction of tissue micorarrays to improve and streamline all immunohistochemical analyses;selection and macrodissection of frozen and formalin-fixed, paraffin-embedded (FFPE) tissue samples to ensure that appropriate cellular compartments are utilized in experimental studies;antibody optimizations for applications in immunohistochemistry (IHC);performance and analysis of a broad range of IHC stains in mouse and human tissues in direct support of the projects; and isolation of nuclei acid extractions from all tissue types (fresh frozen and archival FFPE) for molecular analyses. Finally, the Core will evaluate and implement novel technologies such as ex vivo incubation of Gl tumor sections and their subsequent molecular characterization in response to treatment, multiplexing of biomarkers and sophisticated cellular imaging techniques.
The Pathology Core is an essential partner contributing to the success of all projects in the Gl SPORE. The presence of a centralized lab supporting each project will avoid redundancy in methodologies, will provide cutting edge molecular pathology methodologies and apply them to Gl cancers, and ultimately help guide novel diagnostic and therapeutic discovery.
Cao, Yin; Wu, Kana; Mehta, Raaj et al. (2018) Long-term use of antibiotics and risk of colorectal adenoma. Gut 67:672-678 |
Barry, Joseph D; Fagny, Maud; Paulson, Joseph N et al. (2018) Histopathological Image QTL Discovery of Immune Infiltration Variants. iScience 5:80-89 |
Danai, Laura V; Babic, Ana; Rosenthal, Michael H et al. (2018) Altered exocrine function can drive adipose wasting in early pancreatic cancer. Nature 558:600-604 |
Grasso, Catherine S; Giannakis, Marios; Wells, Daniel K et al. (2018) Genetic Mechanisms of Immune Evasion in Colorectal Cancer. Cancer Discov 8:730-749 |
Corcoran, Ryan B; André, Thierry; Atreya, Chloe E et al. (2018) Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer. Cancer Discov 8:428-443 |
Song, Mingyang; Wu, Kana; Meyerhardt, Jeffrey A et al. (2018) Fiber Intake and Survival After Colorectal Cancer Diagnosis. JAMA Oncol 4:71-79 |
Babic, A; Schnure, N; Neupane, N P et al. (2018) Plasma inflammatory cytokines and survival of pancreatic cancer patients. Clin Transl Gastroenterol 9:145 |
Lopes-Ramos, Camila M; Kuijjer, Marieke L; Ogino, Shuji et al. (2018) Gene Regulatory Network Analysis Identifies Sex-Linked Differences in Colon Cancer Drug Metabolism. Cancer Res 78:5538-5547 |
Van Blarigan, Erin L; Ou, Fang-Shu; Niedzwiecki, Donna et al. (2018) Dietary Fat Intake after Colon Cancer Diagnosis in Relation to Cancer Recurrence and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev 27:1227-1230 |
Patra, Krushna C; Kato, Yasutaka; Mizukami, Yusuke et al. (2018) Mutant GNAS drives pancreatic tumourigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism. Nat Cell Biol 20:811-822 |
Showing the most recent 10 out of 590 publications